

6 LITERATUR

1. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC:
Edema of cardiac origin. Studies of body water and sodium, renal function,
hemodynamic indexes and plasma hormones in untreated congestive cardiac
failure
Circulation 80 (1989): 299-305
2. Bayliss J, Norrel M, Canepa-Ansom R, Sutton G, Poole-Wilson P:
Untreated heart failure: clinical and neuroendocrine effects of introducing
diuretics.
Br Heart J. 57(1987): 17-22
3. Brater DC:
Resistance to loop diuretics. Why it happens and what to do about it.
Drugs 30 (1985): 427-443
4. Brater DC:
Furosemide in patients with heart failure: Shift in dose-response curves
Clin. Pharmacol. Ther. 28 (1980): 182-186
5. Brater DC:
Loop diuretics: transforming pharmacokinetics into better clinical results.
Eur Heart J Supplements 3 (2001): G 19-24
6. Cannon PJ:
The kidney in heart failure.
New Engl J. Med. 296 (1977): 26-32
7. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R:
The effect of mini-dose aspirin on renal funktion and uric acid handling in elderly
patients.
Arthritis Rheum 43 (2000): 103-108
8. Christ M, Grimm W, Maisch B:
Stellenwert der aldosteronantagonistischen Therapie.
Internist 45 (2004): 347-354
9. CIBIS-II Investigators and Committees:
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Lancet 353 (1999): 9-13

10. Cohn J; Levine T; Olivari M:
Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure.
New Engl J. Med. 311 (1984): 819-823
11. Cohn JN, Johnson G, Ziesche S:
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
New Engl J. Med. 325 (1991): 303-310
12. The Consensus Trial Study Group:
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus).
New Engl J. Med. 316 (1987): 1429-1436
13. Cosin J, Diez J:
Torasemid in chronic heart failure: results of the TORIC-Study
Eur J Heart Failure 4 (2002): 507-513
14. Diez J, et al:
Effects of xipamid on transmembranary potassium movements and prostacyclin production.
Nephrology 18 (1987): 57-58
15. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ:
Renal and extrarenal effects of furosemide in congestive heart failure after AMI
New Engl. J. Med. 288 (1973): 1087-1090
16. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S:
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).
Circulation 82 (1990):1724-1729
17. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D'Aiello N, Fucili A, Valgimigli M, Ferrari R:
Neurohormonal modulation in chronic heart failure
Eur Heart J Supplements 2002; 4 (Suppl D): D3-11
18. Gentilini P, La Villa G, Marra F, Carloni V, Melani L, Foschi M, Cotrizzi G, Quartini M:
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
J hepatol 25 (1996): 481-490

19. Greven J, Farjam A:
Characterisation of the renal effects of xipamid in rats.
In: Puschett J.B., Greenberg A. (eds) Diuretics III. Chemistry, Pharmacology, and Clinical Applications. New York, Amsterdam, London: Elsevier. 1990: 186-194
20. Gottlieb SS, Katta M, Wentworth D, Roffmann D, Fisher ML, Kramer WG:
Effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torasemide in patients with heart failure.
Am J Med 104 (1998): 533-538
21. Hall D:
Controversies in heart failure. Are beneficial effects of ace-inhibitors attenuated by aspirin in patients with heart failure?
Cardiol Clin. 19 (2001): 597-603
22. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ.:
Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.
J Am Coll Cardiol. 25(1995):1154-1161
23. Hempelmann, FW:
Die Proteinbindung von Xipamid
Drug Res. 25(1975):258-259
24. Hoppe U, Erdmann E:
Leitlinien zur Therapie der chronischen Herzinsuffizienz
Zeitschrift f. Kardiologie, 90 (2001): 218-237
25. Hunt et al:
ACC/ AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the Task Force on practise guidelines (2001): ACC-Web site www.acc.org
Circulation, 104 (2001): 2996-3007
26. Johnson W, Omland T, Hall C, Lucas C, Mykink OL, Collins C, Pfeffer M, Rouleau JL, Stevenson LW:
Neurohormonal activation rapidly decreases after iv-therapy with diuretics and vasodilators for class IV heart failure.
JACC 39(2002):1623-1629
27. Knauf H:
Therapie mit Diuretika.
Internist 33 (1992): W 113-125
28. Knauf H, Mutschler E:
Pharmakodynamic and kinetic considerations on diuretics as a basis for differential therapy.
Klin Wochenschr 69 (1991): 239-250

29. Knauf H, Mutschler E:
Pharmacodynamics and pharmacokinetics of xipamid in patients with normal and impaired kidney funktion.
Eur J Clin Pharmacol 26(1984):513-520
30. Kramer BK, Schweda F, Riegger GA:
Diuretic treatment and diuretic resistance in heart failure
Am J Med. 106 (1999): 90-96
31. Kult J, Larrat V:
Xipamid bei chronischem Nierenversagen: therapeutische Erfahrungen.
Nieren- und Hochdruckkrankheiten
Zeitschrift für klin. Nephrologie 24 (1995):1-11
32. Lahav M, Regev A, Ra'anani P:
Intermittent administration of furosemide vs. continous infusion preceded by a loading dose for congestive heart failure.
Chest 102 (1992):725-731
33. McMurray, J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, Maggioni A, Pina I, Soler-Soler J, Swedberg K:
Practical recommendations for the use of ACE inhibitors. β -blockers and spironolactone in heart failure: Putting guidelines into practice.
Eur J Heart Failure 3 (2002): 495-502
34. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic hear failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
Lancet 353 (1999): 2001-2007
35. Mühlbauer B:
Furosemid
DMW 125 (2000): 597-598
36. Murray MD, Haag KM, Black PK, Hall SD, Brater DC:
Variable furosemide absorption and poor predictability of response in elderly patients.
Pharmacotherapy 17 (1997): 98-106
37. Neuberg G, Miller A, O'Conner C, Belkin R et al, Packer M for the PRAISE Investigators:
Diuretic resistance predicts mortality in Patients with advanced heart failure.
Am Heart J. 144(2002): 31-38
38. Packer M, Bristow MR, Cohn J, for the US Carvedilol Heart Failure Study Group:
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
N Engl J Med 334 (1996): 1349-1355

-
39. Packer M, O'Connor M, Ghalil JK:
Effect of amlodipine on morbidity and mortality in severe chronic heart failure.
N Engl J Med 335 (1996): 1107-1114
 40. Packer M, Coats AJS, Fowler MB:
Effect of Carvedilol on survival in severe chronic heart failure.
N Engl J Med 344 (2001): 1651-1658
 41. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL:
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Circulation 106 (2002):2194-2199
 42. Paul S:
Balancing diuretic therapy in heart failure: loop diuretics, thiazids and aldosterone antagonists
CHF 8(2002): 307-312
 43. Perry G, et al (The Digitalis Investigation Group):
The effect of digoxin on mortality and morbidity in patients with heart failure.
N Engl J Med 336 (1997): 525-533
 44. Pickkers P:
Direct vascular effects of furosemide in humans.
Circulation 96 (1997):1847-1852
 45. Mühlbauer B:
Furosemid
Dsch med Wschr 125 (2000): 597-598
 46. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J:
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The Randomized Aldactone Evaluation Study Investigators.
N Engl J. Med 341 (1999):709-717
 47. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 348 (2003):1309-1321
 48. Prichard BNC, Brogden, RN:
Xipamid. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Drugs 30 (1985): 313-331

49. Ravnán SL, Ravnán MC, Deedwania PC:
Diuretic resistance and strategies to overcome resistance in patients with CHF.
CHF 2 (2002): 80-85
50. Ring-Larsen H:
Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.
Br Med J 292 (1986):1351-1353
51. Sandhofer A, Kähler C, Heining D, Bellmann R, Wiedermann CJ, Joannidis M:
Severe electrolyte disturbances and renal failure in elderly patients with combined diuretic therapy including xipamid
Wien Klin Wochenschr 114 (2002): 938-942
52. Schüren KP:
Die Behandlung der Herzinsuffizienz mit Diuretika
Verh. Dtsch. Ges. Herz- u. Kreislaufforsch. 48 (1982): 124-138
53. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH:
Diuretic therapy for hypertension and the risk of primary cardiac arrest
NEJM 330 (1994): 1852-1957
54. Taylor SH:
Refocus on diuretics in the treatment of heart failure.
Eur Heart J 16 Suppl F (1995): 7-15
55. Spironolacton
Fachinformationsverzeichnis Deutschland. BPI Service GmbH, abrufbar unter www.fachinfo.de
56. Steffgen J, Müller GA:
Diuretika bei Herzinsuffizienz.
Internist 39 (1998): 320-327
57. The SOLVD Investigators:
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med 325 (1991): 293-302
58. Struthers AD:
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
J Card Fail. 2 (1996): 47-54

-
59. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L:
Hormons regulating cardiovascular funktion in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group
Circulation 82 (1990): 1730-1736
 60. Teichholz LE, Kreulen T, Herman MV, Gorlin R:
Problems in echocardiographic volume determination: echocardiographic-angiographic correlations in the presence or absence of asynergy.
Am J Cardiol. 37 (1976): 7-11
 61. Torasemid versus Furosemid in der Behandlung der chronischen Herzinsuffizienz
Der Arzneimittelbrief 36, 2002: 21b
 62. Van Zwieten PA:
Neuroendocrine effects of diuretics in heart failure.
Brit. Heart J. 72 (Supplement) (1994): S 51-53
 63. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC:
Bioavailability, pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with congestive heart failure.
Clin Pharmacol Ther 57 (1995): 601-609
 64. Vasavada N, et al:
A doubleblind randomised crossover trial of two loop diuretics in chronic kidney disease
Kidney Int 64 (2003): 632-640
 65. Voltz G:
Verhalten von Elektrolyt- und Säure-Basen-Haushalt unter besonderer Berücksichtigung des Kaliumhaushaltes während der Behandlung mit Xipamid
Drug Research 25 (1975):256-258
 66. Watkins L, Burton J, Haber E, Cant J, Smith F, Barger A:
The renin-angiotensin-aldosteron-system in congestive heart failure in conscious dogs.
J Clin Invest 57(1976): 1606-1617
 67. Zannad F:
Evidenced-based drug therapy for chronic heart failure:
Eur Heart J Supplements 2002; 4 (Suppl D): D 66-72

